{"schema_version":"secwatch.filing_event.v1","accession":"0001553350-22-000721","form_type":"8-K","ticker":"PDEX","cik":"0000788920","company_name":"PRO DEX INC","filed_at":"2022-08-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.152272+00:00","generated_at":"2026-06-23T21:32:26.321897+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Pro-Dex Q4 revenue up 34% to $12.6M; full-year net income $3.9M","bullets":["Q4 net sales $12.6M (+34% YoY); net income $1.4M ($0.38/diluted) vs $0.8M ($0.20) in Q4 FY21.","Full-year net sales $42.0M (+11% YoY); net income $3.9M ($1.02/diluted) vs $5.8M ($1.48) in FY21.","Q4 gross margin fell to 27% from 33% due to component price increases outpacing pass-through.","Largest customer orthopedic device sales rose $3.8M in FY22 on next-gen handpiece launch.","CEO cites positive outlook with new building capacity; company does not provide guidance."],"urls":{"canonical":"https://secwatch.observer/filing/0001553350-22-000721","json":"https://secwatch.observer/filing/0001553350-22-000721.json","markdown":"https://secwatch.observer/filing/0001553350-22-000721.md","text":"https://secwatch.observer/filing/0001553350-22-000721.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/788920/000155335022000721/0001553350-22-000721-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/788920/000155335022000721/pdex_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T21:32:26.321897+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}